No neural tube defects among pregnancies with periconception dolutegravir exposure in the Dolomite-EPPICC cohort study
17 April 2020. Related: Conference reports.
Conference reports
Conference on Retroviruses and Opportunistic Infections (CROI 2020)
12 March 2020. Related: Conference reports.
CROI 2020: Special session on COVID-19
12 March 2020. Related: Conference reports, Virology, COVID-19: pathogenesis, COVID-19: on the web.
Monthly islatravir for PEP and PrEP: 12 pills a year could cover unmet need for HIV prevention in billions of people globally
12 March 2020. Related: Conference reports, HIV prevention and transmission.
Long-acting cabotegravir and rilpivirine injections support two-monthly dosing
12 March 2020. Related: Conference reports, Antiretrovirals.
Safety and PK of bNAb elipovimab (GS-9722) support two-weekly dosing
12 March 2020. Related: Conference reports, Antiretrovirals.
First results with long-acting capsid inhibitor GS-6207: oral and subcutaneous formulations for use in naïve and multidrug resistance
12 March 2020. Related: Conference reports, Antiretrovirals.
Predicted diabetes risk with first-line ART regimens: results from the ADVANCE trial
12 March 2020. Related: Conference reports, Side effects.
Postpartum weight gain is higher with dolutegravir- compared with efavirenz-based ART among African women
12 March 2020. Related: Conference reports, Pregnancy, Side effects.
London patient is second person to be cured of HIV from allogeneic stem-cell transplant
12 March 2020. Related: Conference reports, Cure-related research.
The London Patient tells his story as second person cured of HIV
12 March 2020. Related: Conference reports, Cure-related research.
17th European AIDS Conference (EACS 2019)
24 February 2020. Related: Conference reports.
Long-acting cabotegravir and rilpivirine: similar results in women and men
24 February 2020. Related: Conference reports, Antiretrovirals, Women's health.
Antiretroviral pregnancy registry: dolutegravir update
24 February 2020. Related: Conference reports, Pregnancy.
Bictegravir/emtricitabine/tenofovir alafenamide appears to be safe and effective in women: results from a pooled analysis
24 February 2020. Related: Conference reports, Pregnancy.
No HIV transmission among Swiss infants born to mothers with undetectable viral load and who did not receive neonatal PEP
24 February 2020. Related: Conference reports, HIV prevention and transmission.
17th European AIDS Conference (EACS 2019)
13 December 2019. Related: Conference reports.
Capsid inhibitor GS-6207 (lenacapavir): potential for 6 monthly dosing for MDR HIV
13 December 2019. Related: Conference reports, Antiretrovirals.
Dolutegravir/lamivudine as dual ART
13 December 2019. Related: Conference reports, Antiretrovirals.
Weight changes with doravirine-based first line therapy
13 December 2019. Related: Conference reports, Antiretrovirals, Side effects.
Bone and renal changes in the ADVANCE trial
13 December 2019. Related: Conference reports.
10th International Workshop on HIV and Ageing
13 December 2019. Related: Conference reports, Ageing and life expectancy.
Impact of isolation and loneliness on older people living with HIV
13 December 2019. Related: Conference reports, Ageing and life expectancy.
17th European AIDS Conference (EACS 2019)
15 November 2019. Related: Conference reports.
EACS launch major update to European Treatment Guidelines (November 2019)
15 November 2019. Related: Conference reports, Guidelines.
Weight gain and metabolic syndrome with dolutegravir and TAF: results from the ADVANCE trial
15 November 2019. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
10th International Workshop on HIV and Ageing
15 November 2019. Related: Conference reports, Ageing and life expectancy.
Frailty in HIV care and the importance of lifestyle changes
15 November 2019. Related: Conference reports, Ageing and life expectancy.
Research into use of medicinal cannabis in HIV management
15 November 2019. Related: Conference reports, Ageing and life expectancy.
Vaping can help HIV positive smokers who are not motivated to quit cigarettes
15 November 2019. Related: Conference reports, Coinfections and complications, Cancer and HIV, Ageing and life expectancy.
IDWeek (2019), 2–6 October 2019, Washington DC
18 October 2019. Related: Conference reports.
HIV suppression and safety with ibalizumab at 48 weeks in expanded access
18 October 2019. Related: Conference reports, Antiretrovirals.
Oral cabotegravir and rilpivirine is durable for 5.5 years in LATTE study
18 October 2019. Related: Conference reports, Antiretrovirals.
Dolutegravir plus rilpivirine had good virologic, safety record in clinics before single tablet available
18 October 2019. Related: Conference reports, Antiretrovirals.
Switching from TDF to TAF linked to higher BMI and cardio risk
18 October 2019. Related: Conference reports, Antiretrovirals, Side effects.
Possible higher diabetes risk with raltegravir or PIs than NNRTIs
18 October 2019. Related: Conference reports, Antiretrovirals, Side effects.
Fostemsavir interaction study flags strong CYP3A inducers, statins, oral contraceptives
18 October 2019. Related: Conference reports, PK and drug interactions.
Over half of mostly black US HIV group has NAFLD – and many have NASH
18 October 2019. Related: Conference reports, Lipodystrophy and metabolic complications.
People taking more medications and women have higher fall risk in older HIV group
18 October 2019. Related: Conference reports, Coinfections and complications, Ageing and life expectancy.
No link between raltegravir and adverse birth outcomes in analysis in 2550 women
18 October 2019. Related: Conference reports, Pregnancy.
PrEP linked to lower HIV incidence in US, independent of TasP
18 October 2019. Related: Conference reports, HIV prevention and transmission.
10th IAS Conference on HIV Science (IAS 2019): final reports
30 September 2019. Related: Conference reports.
Low rates of pregnancy with three methods of contraception in the ECHO trial
30 September 2019. Related: Conference reports, Pregnancy.
Other pregnancy studies IAS 2019
17 September 2019. Related: Conference reports, Pregnancy.
10th IAS Conference on HIV Science (IAS 2019) in Mexico City
23 August 2019. Related: Conference reports.
Four days on, three days off is NOT as effective as daily ART: French study results need to be interpreted with caution
23 August 2019. Related: Conference reports, Treatment strategies.
Switching to bictegravir/F/TAF in virally suppressed participants – including analyses by baseline drug resistance
23 August 2019. Related: Conference reports, Antiretrovirals.
Dolutegravir-based first-line non-inferior to efavirenz-based ART but associated with substantial weight gain: results from the ADVANCE study
23 August 2019. Related: Conference reports, Antiretrovirals, Treatment strategies, Side effects.
Dolutegravir for younger children: results from the ODYSSEY trial
23 August 2019. Related: Conference reports, Paediatric care.
PK advantages of TAF/FTC over TDF/FTC for HIV PrEP might compensate for low adherence: sub-analysis of DISCOVER study
23 August 2019. Related: Conference reports, HIV prevention and transmission.
10th IAS Conference on HIV Science (IAS 2019) in Mexico City
24 July 2019. Related: Conference reports.
Dolutegravir neural tube defect risk declines but still slightly higher than with other antiretrovirals
24 July 2019. Related: Conference reports, Pregnancy.
WHO recommends dolutegravir-based ART regimens for all
24 July 2019. Related: Conference reports, Guidelines.
High rates of viral suppression with low dose efavirenz in pregnant Zambian women
24 July 2019. Related: Conference reports, Pregnancy.
First viral load results for capsid inhibitor GS-6207: mean –2.2 log reduction at day 10
24 July 2019. Related: Conference reports, Antiretrovirals.
Islatravir (MK-8591) with doravirine plus lamivudine: 24 week results
24 July 2019. Related: Conference reports, Antiretrovirals.
Dual therapy with islatravir (MK-8591) plus doravirine: 24 week results as switch strategy
24 July 2019. Related: Conference reports, Antiretrovirals.
Fostemsavir: 96-week follow-up in people with multi-drug resistance
24 July 2019. Related: Conference reports, Antiretrovirals.
Dolutegravir/lamivudine dual therapy non-inferior to triple ART at week-96
24 July 2019. Related: Conference reports, Antiretrovirals.
Switching to dolutegravir/lamivudine dual therapy is non-inferior to TAF-based triple therapy at week-48 in TANGO study
24 July 2019. Related: Conference reports, Antiretrovirals.
Islatravir (MK-8591) implant sustains HIV PrEP protection for more than one year
24 July 2019. Related: Conference reports, HIV prevention and transmission.
Upcoming 10th IAS Conference on HIV Science (IAS 2019)
17 July 2019. Related: Conference reports.
IAS 2019: late breaker highlights to look for
17 July 2019. Related: Conference reports, Antiretrovirals.
20th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs
19 June 2019. Related: Conference reports.
Efavirenz 600 mg exposure appears sufficient with high-dose daily rifapentine
19 June 2019. Related: Conference reports, PK and drug interactions, TB coinfection.